Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov:82:100916.
doi: 10.1016/j.resmer.2022.100916. Epub 2022 Jul 25.

Asthma and smoking: A review

Audrey Kamga  1 , Cécile Rochefort-Morel  2 , Yannick Le Guen  3 , Hakima Ouksel  4 , Anais Pipet  5 , Christophe Leroyer  6
Affiliations
Review

Asthma and smoking: A review

Audrey Kamga et al. Respir Med Res. 2022 Nov.

Abstract

Asthma occurrence is often associated with cigarette smoking. Surprisingly, active smokers are excluded from most clinical studies. Prevalence of asthma associated with smoking appears to be similar to asthma in the general population. However, in active smokers, asthma tends to be more difficult to manage and more severe. Several studies have demonstrated a poor response to inhaled corticosteroids (ICS) and an accelerated decline of lung function. Smoking decreases exhaled NO rate and down-regulates ICS receptors, which is associated with increased oxidative stress. Data on biologic therapies are scarce. Finally, nicotine dependence seems higher in asthmatic patients and smoking cessation is thus more difficult.

Keywords: Asthma; Smoking; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Audrey Kamga: none. Dr Rochefort-Morel reported fees for board memberships or symposia from, GSK, ALK, Stallergenes, Chiesi, Menarini, Sanofi, Astra, Boerhinger, Mylan, Mundipharma. Dr Le Guen: none. Dr Ouksel reported receiving fees for board memberships or symposia from Novartis, Chiesi, GSK, Astra Zeneca, LFB and CSL Behring. Dr Pipet reported receiving fees for board memberships or symposia from Asten Santé, Astra-Zeneca Boehringer and Novartis. Dr Leroyer reported receiving fees for board memberships or symposia from GlaxoSmithKline, AstraZeneca, ALK, Chiesi, Ménarini, Novartis, Pfizer, Sanofi, and MSD.

Substances